Saturday 17 October 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
36.35
0.02
+0.06%
Follow PCRX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 17.70 | 63.34 | 109.50 | 35.56 | 0.00 | 172.53 |
Piotroski F-Score |
4 | 5 | 6 | 5 | 4 | 4 | 6 | 8 | 5 | 8 |
P/S ratio |
4.68 | 6.43 | 5.22 | 4.47 | 5.94 | 4.92 | 2.65 | 2.19 | 1.24 | 1.59 |
Altman Z-Score |
3.99 | 3.22 | 3.37 | 2.68 | 2.89 | 1.65 | 1.80 | 2.16 | 1.12 | 2.02 |
P/FCF ratio |
147.98 | 0.00 | 51.23 | 31.15 | 65.09 | 33.35 | 15.36 | 10.60 | 4.87 | 8.44 |
Altman Z″-Score (non-manufacturers) |
1.22 | 2.05 | 3.21 | 1.68 | 2.64 | 1.62 | 2.22 | 3.17 | 2.14 | 3.08 |
Beneish M-Score |
(3.08) | (2.80) | (2.77) | (2.08) | (2.05) | (1.99) | (2.67) | (2.71) | (3.48) | (2.93) |
P/Operating CF |
74.58 | 108.85 | 82.94 | 72.60 | 54.72 | 114.72 | 42.08 | 31.08 | 26.30 | 26.40 |
P/B ratio |
5.91 | 6.59 | 5.48 | 5.30 | 4.12 | 3.65 | 2.28 | 1.70 | 1.12 | 1.66 |
Price to Tangible BV |
7.51 | 8.22 | 6.79 | 12.45 | 6.03 | 0.00 | 24.84 | 6.61 | 2.47 | 3.78 |
EV/Sales |
4.45 | 6.31 | 4.94 | 4.51 | 5.82 | 5.00 | 3.25 | 2.55 | 1.39 | 2.05 |
EV/EBITDA |
0.00 | 3,188.44 | 38.35 | 41.74 | 28.87 | 18.74 | 13.67 | 10.61 | 799.97 | 13.76 |
EV/Operating CF |
36.77 | 101.65 | 34.11 | 26.94 | 32.48 | 21.52 | 14.94 | 11.14 | 5.13 | 9.80 |
EV/FCF |
140.68 | (1,220.69) | 48.53 | 31.47 | 63.77 | 33.88 | 18.84 | 12.35 | 5.44 | 10.90 |
Quick Ratio |
4.52 | 6.10 | 6.95 | 3.15 | 2.27 | 1.44 | 2.62 | 3.94 | 1.93 | 3.01 |
Current Ratio |
5.42 | 6.96 | 7.88 | 3.79 | 2.57 | 1.66 | 3.37 | 5.24 | 2.40 | 4.54 |
Net Debt/EBITDA |
4.39 | (62.04) | (2.14) | 0.42 | (0.60) | 0.29 | 2.53 | 1.50 | 82.89 | 1.24 |
Debt/Assets |
27.78% | 43.95% | 42.15% | 37.43% | 36.88% | 33.67% | 41.01% | 33.18% | 37.68% | 29.42% |
Debt/Equity |
0.50 | 0.99 | 0.90 | 0.88 | 0.76 | 0.96 | 0.89 | 0.60 | 0.75 | 0.54 |
Asset Turnover |
0.71 | 0.56 | 0.51 | 0.55 | 0.41 | 0.32 | 0.36 | 0.41 | 0.45 | 0.52 |
Operating CF/Net income |
(0.88) | (0.42) | (103.76) | (6.40) | 0.53 | 2.99 | 9.13 | 3.69 | (1.90) | 21.61 |
Capex/Depreciation |
(1.41) | (0.76) | (0.53) | (0.29) | (0.94) | (0.84) | (0.30) | (0.20) | (0.14) | (0.17) |
Interest Coverage |
(4.54) | (1.38) | 0.73 | 0.44 | 1.81 | 2.83 | 1.50 | 4.32 | (4.43) | 1.10 |
| (17.35%) | (17.10%) | (0.16%) | (3.26%) | 29.86% | 6.22% | 2.11% | 5.10% | (12.08%) | 0.96% | |
| (9.74%) | (8.36%) | (0.07%) | (1.45%) | 13.82% | 2.51% | 0.85% | 2.58% | (6.37%) | 0.50% | |
ROIC |
(12.90%) | (6.38%) | 4.36% | 1.75% | 5.10% | 7.27% | 3.19% | 4.92% | (5.22%) | 1.45% |
Return on Tangible Assets |
(12.68%) | (9.64%) | (0.09%) | (2.72%) | 27.20% | 7.87% | 2.98% | 7.15% | (16.53%) | 1.24% |
Average Days of Receivables |
39.54 | 40.31 | 41.12 | 41.21 | 45.06 | 64.92 | 53.86 | 57.08 | 59.00 | 62.34 |
Research and Development Expense of Revenue |
16.53% | 19.99% | 16.51% | 17.13% | 13.83% | 10.26% | 12.72% | 11.30% | 11.64% | 16.15% |
Selling, General and Administrative Expense of Revenue |
55.22% | 56.34% | 52.56% | 47.69% | 45.04% | 36.81% | 38.17% | 39.92% | 41.96% | 50.76% |
Intangible Assets out of Total Assets |
0.12 | 0.09 | 0.09 | 0.25 | 0.15 | 0.37 | 0.42 | 0.41 | 0.27 | 0.31 |
Share Based Compensation of Revenue |
11.31% | 11.03% | 9.41% | 7.99% | 9.29% | 7.80% | 7.21% | 7.10% | 7.30% | 7.92% |
Graham Net Nets |
0.05 | 0.02 | 0.06 | (0.04) | 0.00 | (0.18) | (0.23) | (0.13) | (0.03) | (0.02) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 33.23 | 18.78 | 11.66 | 19.52 | 0.00 | 7.25 |
Earnings Yield |
(2.91%) | (2.35%) | (0.04%) | (0.60%) | 5.65% | 1.58% | 0.91% | 2.81% | (11.46%) | 0.58% |
Free Cash Flow Yield |
0.68% | (0.08%) | 1.95% | 3.21% | 1.54% | 3.00% | 6.51% | 9.43% | 20.52% | 11.85% |
Revenue per Share |
7.42 | 7.20 | 8.24 | 10.14 | 10.07 | 12.23 | 14.65 | 14.60 | 15.16 | 16.30 |
Operating CF per Share |
0.90 | 0.45 | 1.19 | 1.70 | 1.81 | 2.84 | 3.19 | 3.35 | 4.10 | 3.41 |
Capex per Share |
(0.66) | (0.48) | (0.35) | (0.24) | (0.89) | (1.04) | (0.66) | (0.33) | (0.23) | (0.34) |
Free Cash Flow per Share |
0.23 | (0.04) | 0.84 | 1.45 | 0.92 | 1.80 | 2.53 | 3.02 | 3.87 | 3.07 |
Cash per Share |
4.64 | 7.82 | 9.37 | 7.03 | 12.23 | 14.83 | 6.34 | 6.03 | 10.48 | 5.35 |
Shareholders Equity per Share |
5.88 | 7.02 | 7.85 | 8.55 | 14.52 | 16.50 | 17.03 | 18.83 | 16.83 | 15.55 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.88 | 7.02 | 7.85 | 8.55 | 14.52 | 16.50 | 17.03 | 18.83 | 16.83 | 15.55 |
Free Cash Flow |
8.74 | (1.48) | 34.36 | 60.36 | 39.23 | 79.85 | 115.20 | 139.49 | 178.75 | 136.66 |
Working Capital |
198.25 | 334.89 | 417.31 | 300.88 | 398.30 | 344.93 | 350.56 | 412.61 | 435.21 | 427.38 |
Capital Expenditures |
(24.71) | (19.27) | (14.51) | (10.16) | (37.80) | (45.87) | (30.08) | (15.16) | (10.64) | (15.33) |
Net Current Asset Value |
70.60 | 42.22 | 109.84 | (67.56) | (3.20) | (478.90) | (407.86) | (194.26) | (30.04) | (23.83) |
EV/EBIT |
0.00 | 0.00 | 104.75 | 181.26 | 53.98 | 30.09 | 36.15 | 19.65 | 0.00 | 77.62 |
Capex to Sales |
0.09 | 0.07 | 0.04 | 0.02 | 0.09 | 0.08 | 0.05 | 0.02 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 110.59 | 179.44 | 55.09 | 29.62 | 29.47 | 16.87 | 0.00 | 60.10 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.17 | 0.24 | 0.25 | 0.33 | 0.30 | 0.29 | 0.54 | 0.43 | 0.45 | 0.63 |
Cash ROIC |
1.75% | (0.17%) | 3.45% | 6.30% | 2.43% | 3.83% | 6.57% | 8.35% | 9.67% | 10.48% |
Accounts Receivable Turnover |
9.91 | 9.31 | 9.68 | 9.85 | 8.54 | 7.25 | 6.85 | 6.62 | 6.41 | 6.12 |
Accounts Payable Turnover |
13.55 | 7.93 | 5.98 | 7.86 | 10.10 | 13.37 | 15.47 | 11.95 | 9.79 | 8.74 |
Inventory Turnover |
2.37 | 2.42 | 1.93 | 2.00 | 1.91 | 1.72 | 2.05 | 1.84 | 1.48 | 1.08 |
Average Days of Payables |
24.90 | 60.86 | 60.39 | 43.78 | 32.45 | 27.44 | 27.87 | 31.03 | 40.98 | 36.93 |
Days of Inventory on Hand |
103.69 | 171.93 | 204.13 | 199.40 | 201.12 | 256.47 | 175.94 | 206.25 | 268.31 | 372.59 |
Average Receivables |
27.90 | 30.80 | 34.83 | 42.77 | 50.29 | 74.68 | 97.36 | 101.98 | 109.43 | 118.69 |
Average Payables |
8.13 | 11.08 | 14.51 | 13.58 | 11.62 | 10.49 | 12.88 | 15.46 | 17.42 | 17.14 |
Average Inventory |
46.46 | 36.34 | 44.99 | 53.43 | 61.47 | 81.60 | 97.31 | 100.21 | 114.82 | 139.07 |
Average Assets |
389.60 | 509.92 | 658.86 | 760.21 | 1,052.79 | 1,674.93 | 1,878.28 | 1,627.79 | 1,563.95 | 1,409.22 |
Average Common Equity |
218.68 | 249.23 | 300.35 | 338.09 | 487.32 | 675.05 | 752.71 | 822.57 | 824.24 | 735.73 |
Columns are period end dates